Three medical technology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

iCAD, Inc. (ICAD) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Icad is a provider of advanced image analysis and workflow solutions that enable radiologists and other healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. In Portfolio Grader’s specific subcategory of Earnings Revisions, ICAD also gets an A. For more information, get Portfolio Grader’s complete analysis of ICAD stock.

Omnicell, Inc. (OMCL) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Omnicell provides an integrated suite of clinical infrastructure and workflow automation solutions for healthcare facilities. For more information, get Portfolio Grader’s complete analysis of OMCL stock.

Medidata Solutions, Inc. (MDSO) shows solid improvement this week. The company’s rating rises from a B to an A. Medidata Solutions provides hosted clinical development solutions. The stock price has risen 6.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MDSO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.